Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia

Dettagli Bibliografici
Autori principali:	Moorman, A, Harrison, C, Buck, G, Richards, S, Secker-Walker, L, Martineau, M, Vance, G, Cherry, A, Higgins, R, Fielding, A, Foroni, L, Paietta, E, Tallman, MS, Wernik, P, Litzow, MR, Rowe, J, Goldstone, A, Dewald, G
Natura:	Conference item
Pubblicazione:	2007

Documenti analoghi

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia
di: Moorman, A, et al.
Pubblicazione: (2007)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
di: Moorman, A, et al.
Pubblicazione: (2007)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
di: Moorman, A, et al.
Pubblicazione: (2005)

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
di: Fielding, A, et al.
Pubblicazione: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
di: Fielding, A, et al.
Pubblicazione: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
di: Fielding, A, et al.
Pubblicazione: (2010)

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
di: Sive, J, et al.
Pubblicazione: (2012)

Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.
di: Rai, L, et al.
Pubblicazione: (2010)

High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome.
di: Chilton, L, et al.
Pubblicazione: (2014)

High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome
di: Chilton, L, et al.
Pubblicazione: (2014)

High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): Cytogenetic features, clinical characteristics and outcome
di: Chilton, L, et al.
Pubblicazione: (2014)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
di: Rowe, J, et al.
Pubblicazione: (2008)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
di: Fielding, A, et al.
Pubblicazione: (2014)

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
di: Fielding, A, et al.
Pubblicazione: (2009)

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
di: Marks, D, et al.
Pubblicazione: (2009)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
di: Ganzel, C, et al.
Pubblicazione: (2020)

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.
di: Patel, B, et al.
Pubblicazione: (2008)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups
di: Lrrzow, MR, et al.
Pubblicazione: (2010)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
di: Patel, B, et al.
Pubblicazione: (2010)

The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
di: Patel, B, et al.
Pubblicazione: (2005)

Sequential quantitative minimal residual disease in BCR-ABL positive acute lymphoblastic leukaemia: Differential observations between major and minor fusion gene rearrangements and variation due to source material
di: Gerrard, G, et al.
Pubblicazione: (2004)

Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia: early results from the MRC UKALL12 Study
di: Patel, B, et al.
Pubblicazione: (2006)

Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study
di: Fielding, A, et al.
Pubblicazione: (2007)

Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
di: Kumar, A, et al.
Pubblicazione: (2016)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
di: Sive, J, et al.
Pubblicazione: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
di: Sive, J, et al.
Pubblicazione: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
di: Sive, J, et al.
Pubblicazione: (2010)

Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.
di: Chopra, R, et al.
Pubblicazione: (2003)

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.
di: Harrison, C, et al.
Pubblicazione: (2004)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
di: Lrrzow, MR, et al.
Pubblicazione: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
di: Lrrzow, MR, et al.
Pubblicazione: (2010)

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
di: Goldstone, A, et al.
Pubblicazione: (2008)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
di: Fielding, A, et al.
Pubblicazione: (2007)

Outcome in Philadelphia Chromosome Positive (Ph plus ) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se
di: Paietta, E, et al.
Pubblicazione: (2008)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
di: Paietta, E, et al.
Pubblicazione: (2008)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
di: Mansour, MR, et al.
Pubblicazione: (2009)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
di: Secker-Walker, L, et al.
Pubblicazione: (1997)

Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long-term follow-up.
di: Secker-Walker, L, et al.
Pubblicazione: (1989)

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
di: Goldstone, A, et al.
Pubblicazione: (1999)

Late relapsing childhood lymphoblastic leukaemia.
di: Frost, L, et al.
Pubblicazione: (1997)